Abstract
Slow-channel congenital myasthenic syndrome (CMS) is a rare subtype of CMS caused by dominant “gain of function” mutations in the acetylcholine receptor. Clinically, the cervical and forearm extensor muscles seem to be preferentially weaker; and conventional treatment with anticholinesterases fails to improve symptoms. In contrast, open channel blockers such as fluoxetine and quinidine have been shown to be of benefit. The objectives of our study were to provide further insight into the clinical features of slow-channel CMS and evaluate response to recommended therapy. We carried out a retrospective clinical follow up study of 15 slow-channel CMS patients referred to the Munich CMS Centre. Detailed clinical data were collected by clinicians involved in the care of each patient, with a particular focus on response and tolerability to recommended therapy. Patients varied widely as regard onset of symptoms, severity of disease and mutations involved. Patients received up to four different medications and some had none. Our results strengthen previous reported findings in terms of clinical phenotype variability and the poor response to pyridostigmine. Although treatment with fluoxetine was beneficial in most patients, a number of our patients suffered significant adverse effects that hindered optimum dose titration or led to treatment cessation. Slow-channel CMS is rare and exhibits distinct clinical and genetic characteristics. Our study suggests that fluoxetine, despite being effective in most patients, can be associated with significant side effects, thus reducing treatment effectiveness in clinical practice.
Similar content being viewed by others
References
Abicht A, Stucka R, Karcagi V, Herczegfalvi A, Horvath R, Mortier W, Schara U, Ramaekers V, Jost W, Brunner J, Janssen G, Seidel U, Schlotter B, Muller-Felber W, Pongratz D, Rudel R, Lochmuller H (1999) A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin. Neurology 53:1564–1569
Beeson D, Hantai D, Lochmuller H, Engel AG (2005) 126th International Workshop: congenital myasthenic syndromes, 24–26 September 2004, Naarden, the Netherlands. Neuromuscul Disord 15:498–512
Colomer J, Muller JS, Vernet A, Nascimento A, Pons M, Gonzalez V, Abicht A, Lochmuller H (2006) Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine. Neuromuscul Disord 16:329–333
Engel AG (2007) The therapy of congenital myasthenic syndromes. Neurotherapeutics 4:252–257
Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN (1982) A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 11:553–569
Engel AG, Ohno K, Milone M, Wang HL, Nakano S, Bouzat C, Pruitt JN 2nd, Hutchinson DO, Brengman JM, Bren N, Sieb JP, Sine SM (1996) New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 5:1217–1227
Engel AG, Sine SM (2005) Current understanding of congenital myasthenic syndromes. Curr Opin Pharmacol 5:308–321
Fukudome T, Ohno K, Brengman JM, Engel AG (1998) Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. Neuroreport 9:1907–1911
Gomez CM, Maselli RA, Vohra BP, Navedo M, Stiles JR, Charnet P, Schott K, Rojas L, Keesey J, Verity A, Wollmann RW, Lasalde-Dominicci J (2002) Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. Ann Neurol 51:102–112
Hantai D, Richard P, Koenig J, Eymard B (2004) Congenital myasthenic syndromes. Curr Opin Neurol 17:539–551
Harper CM, Engel AG (1998) Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 43:480–484
Harper CM, Engel AG (1998) Safety and efficacy of quinidine sulfate in slow-channel congenital myasthenic syndrome. Ann NY Acad Sci 841:203–206
Harper CM, Fukodome T, Engel AG (2003) Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 60:1710–1713
Kinali M, Beeson D, Pitt MC, Jungbluth H, Simonds AK, Aloysius A, Cockerill H, Davis T, Palace J, Manzur AY, Jimenez-Mallebrera C, Sewry C, Muntoni F, Robb SA (2008) Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol 201–202:6–12
Mihaylova V, Scola RH, Gervini B, Lorenzoni PJ, Kay CK, Werneck LC, Stucka R, Guergueltcheva V, von der Hagen M, Huebner A, Abicht A, Muller JS, Lochmuller H (2010) Molecular characterisation of congenital myasthenic syndromes in Southern Brazil. J Neurol Neurosurg Psychiatry 81:973–977
Muller JS, Mihaylova V, Abicht A, Lochmuller H (2007) Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission. Expert Rev Mol Med 9:1–20
Outteryck O, Richard P, Lacour A, Fournier E, Zephir H, Gaudon K, Eymard B, Hantai D, Vermersch P, Stojkovic T (2009) Novel epsilon subunit mutation of the muscle acetylcholine receptor causing a slow-channel congenital myasthenic syndrome. J Neurol Neurosurg Psychiatry 80:450–451
Schara U, Lochmuller H (2008) Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics 5:542–547
Sine SM, Ohno K, Bouzat C, Auerbach A, Milone M, Pruitt JN, Engel AG (1995) Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 15:229–239
Whittington CJ, Kendall T, Pilling S (2005) Are the SSRIs and atypical antidepressants safe and effective for children and adolescents? Curr Opin Psychiatry 18:21–25
Acknowledgments
The Institute of Genetic Medicine in Newcastle is part of the MRC centre for Neuromuscular Diseases. Newcastle University is the coordinating centre of TREAT-NMD (EC, 6th FP, proposal #036825; www.treat-nmd.eu). JSM receives a fellowship by the Medical Faculty of Newcastle University. VG is a research fellow of the Alexander von Humboldt Foundation. AA is supported by a grant from the Deutsche Forschungsgemeinschaft (Ab 130/2-1).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chaouch, A., Müller, J.S., Guergueltcheva, V. et al. A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. J Neurol 259, 474–481 (2012). https://doi.org/10.1007/s00415-011-6204-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-011-6204-9